+

WO2003033007A1 - Pharmaceutical compositions for the topical use containing medicinal plants extracts with antiphlogistic and cicatrising activities - Google Patents

Pharmaceutical compositions for the topical use containing medicinal plants extracts with antiphlogistic and cicatrising activities Download PDF

Info

Publication number
WO2003033007A1
WO2003033007A1 PCT/EP2002/011357 EP0211357W WO03033007A1 WO 2003033007 A1 WO2003033007 A1 WO 2003033007A1 EP 0211357 W EP0211357 W EP 0211357W WO 03033007 A1 WO03033007 A1 WO 03033007A1
Authority
WO
WIPO (PCT)
Prior art keywords
flowers
malva
althaea
cicatrising
pharmaceutical compositions
Prior art date
Application number
PCT/EP2002/011357
Other languages
French (fr)
Inventor
Mario Baraldi
Original Assignee
Mario Baraldi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mario Baraldi filed Critical Mario Baraldi
Publication of WO2003033007A1 publication Critical patent/WO2003033007A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like

Definitions

  • the present invention relates to pharmaceutical compositions for the topical use containing extracts of chamomile heads (Matricaria recutita), althaea roots (Althaea officinalis L.), malva flowers (Malva sylvestris), large- leaved lime flowers (Tillia Platyphyllos) and milfoil flowers (Achillea millefolium L.), endowed with anti-inflammatory and cicatrising properties, for the treatment of skin inflammations and lesions.
  • chamomile heads Matricaria recutita
  • althaea roots Althaea officinalis L.
  • malva flowers Malva sylvestris
  • large- leaved lime flowers Tala Platyphyllos
  • milfoil flowers Adchillea millefolium L.
  • bedsores i.e. skin lesions which, due to reduced tissutal perfusion and loss of skin trophism and elasticity, tend to become chronic, is one of the most widespread consequences of protracted infirmity, especially in the elderly.
  • the accumulation of free radicals reduces the tensile strength of the lesions by inhibiting hyaluronic acid, thus preventing tissutal reparative processes.
  • Healing of skin lesions apparently occurs through a first "inflammatory" phase followed by a neo-angiogenesis and granulation tissue formation phase, with wound contraction and subsequent cicatrization and re-epithelization.
  • Object of the present invention are pharmaceutical compositions for topical use containing extracts of chamomile heads (Matricaria recutit ⁇ ), althaea roots (Althaea officinalis L.), malva flowers (Malva sylvestris), large-leaved lime flowers (Tillia Platyphyllos) and milfoil flowers (Achillea millefolium L.), useful for the treatment of skin infiammations and lesions.
  • extracts of chamomile heads (Matricaria recutit ⁇ ), althaea roots (Althaea officinalis L.), malva flowers (Malva sylvestris), large-leaved lime flowers (Tillia Platyphyllos) and milfoil flowers (Achillea millefolium L.), useful for the treatment of skin infiammations and lesions.
  • Said pharmaceutical compositions are preferably in the form of creams, gels, pastes or ointments, in which the extracts total content ranges from 10 to 40%.
  • a preferred embodiment of the invention consists in a cream containing 20% extracts in Essex ® base cream (hereinafter referred to as BAR 2).
  • BAR 2 The compositions can be prepared from extracts of each vegetable component, or from an extract obtainable from a mixture of all the vegetable components.
  • the liquid phase is recovered by filtration, preferably under vacuum, and evaporated under reduced pressure at a temperature not higher than 35°C.
  • 100 g vegetable components mixture is soaked in a 30/70 v/v distilled water/ethanol mixture, up to 1 litre final volume.
  • BAR 1 The anti-inflammatory and cicatrising properties of the compositions containing the extracts of the invention were evaluated in rats by means of the following tests:
  • Both the extract and the cream showed active, in fact topical application on rat skin reduced in a statistically significant way inflammation and oedema in the carrageenin and dextran oedema tests and enhanced the cicatrising action in the experimental excoriations and ulcers tests.
  • BAR 1 extract was prepared soaking for 24 hours a mixture consisting of 100 g of each vegetable component, suitably ground, in distilled water and ethyl alcohol (30:70 v/v), to a final volume of one litre, stored in a tightly sealed dark vessel.
  • the liquid phase was recovered by filtration under vacuum and the intense green liquid was evaporated under reduced pressure at a temperature of 30-35°C, to avoid degradation.
  • Cream BAR 2 was prepared incorporating 20 g of BAR 1 extract in
  • mice Male Sprague-Dawley rats, (about 120-150 g weight) purchased from Harlan Italy (Udine, Italy), housed in single cages, under controlled temperature and humidity (22 ⁇ 1°C, 60% humidity).
  • Treatments BAR 1 extract or Cream BAR 2 were applied on the area to be treated.
  • a suspension of carrageenin (0.1 ml, 1% in normal saline) was administered to one of the rats hind paws.
  • leg volume was evaluated with a pletismometer (Basile, Varese), prior to carrageenin injection (reference value) and after 2, 4, 8, 24 hours.
  • the values reported in the table refer to percentage increases in the paw volume compared with the reference value.
  • BAR 1 extract was applied to the rat paw immediately after carrageenin injection and after each evaluation. Dextran oedema test
  • a 5% dextran solution (0.1 ml) in saline was administered to one of the rats hind paws.
  • leg volume was evaluated with a pletismometer (Basile, Varese), prior to dextran injection (reference value) and after 2, 4, 8, 24 hours.
  • the values reported in the table refer to percentage increases in the leg volume compared with the reference value.
  • BAR 1 extract was applied to the rat paw immediately after carrageenin injection and after each evaluation.
  • Ketavet (Gellini pharmaceutical), then shaved on the back so as to define a 1.5 cm diameter circular area. After that, the skin was scarified with a scalpel, then Essex ® base cream was applied to control animals, whereas BAR 2 was applied to the treated ones.
  • Table 1 shows that in a 24 hours evaluation BAR 1 reduces carrageenin-induced oedema in a statistically significant way compared with controls, at any surveying time.
  • BAR 1 significantly reduces (table 2) the percentage of paw volume increase induced by dextran, and is particularly active between 4-6 hours.
  • Table N°l Effect induced by BAR 1 on carrageenin oedema in rats
  • Table 3 shows that BAR 2 accelerates cutaneous reparative processes subsequent to excoriations. Values observed at 48, 72 and 96 hours from excoriations are in fact much higher in treated animals than in controls. In particular, the effect is statistically significant at 72 and 96 hours.
  • the results show that BAR 1 extract and the topical pharmaceutical compositions containing it have excellent antiphlogistic and cicatrising activities. Therefore, the pharmaceutical compositions containing the extracts of the invention, in particular BAR 1 extract, can be used in the treatment of skin conditions wherein reduction of inflammation and improvement of tissue repair processes are required, in particular for healing bedsores.

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)

Abstract

Extracts of chamomile heads (Matricaria recutita), althaea roots (Althaea officinalis L.), malva flowers (Malva flowers (Malva sylvestris), large-leaved lime flowers (Tillia Platyphyllos) and milfoil flowers (Achillea millefolium L.) are endowed with anti-inflammatory and cicatrising properties. They can therefore be used for the preparation of topical medicaments for the treatment of skin inflammations, excoriations and ulcers.

Description

PHARMACEUTICAL COMPOSITIONS FOR THE TOPICAL USE CONTAINING MEDICINAL PLANTS EXTRACTS WITH ANTIPHLOGISTIC AND CICATRISING ACTIVITIES
The present invention relates to pharmaceutical compositions for the topical use containing extracts of chamomile heads (Matricaria recutita), althaea roots (Althaea officinalis L.), malva flowers (Malva sylvestris), large- leaved lime flowers (Tillia Platyphyllos) and milfoil flowers (Achillea millefolium L.), endowed with anti-inflammatory and cicatrising properties, for the treatment of skin inflammations and lesions. INTRODUCTION
The formation of bedsores, i.e. skin lesions which, due to reduced tissutal perfusion and loss of skin trophism and elasticity, tend to become chronic, is one of the most widespread consequences of protracted infirmity, especially in the elderly.
The most severe cases can be nowadays treated by means of skin and keratinocytes transplants.
Nevertheless, novel remedies for preventing or healing the lesions at the beginning or at the first evolution steps would be valuable in that they would limit recourse to surgery. Several products for the topical use presently available on the market contain non steroidal or steroidal anti-inflammatory drugs and their prolonged use favours side-effects onset. Therefore, it would be useful to provide for products that contain active natural principles endowed with anti-inflammatory and cicatrising properties. Research for new compounds for the treatment of the above mentioned lesions has focused for some time on natural substances, which are usually better tolerable and lack side effects.
Attention has been centered in particular on chamomile, due to its antiinflammatory and antimicrobial properties. Said properties, particularly in case of topical use, are apparently ascribable only in negligible extent to the essential oil components (camazulene, α-bisabolol, matricine, etc.) and rather to the hydrosoluble components, i.e. flavonoids (apigenin, luteolin, quercitine, ratine and glucoside derivatives). It is assumed that flavonoids act by preventing histamine effects and oxygen free radicals release rather than by inhibiting arachidonic acid pathway. This mechanism could explain not only chamomile antiphlogistic activity, but also its cicatrising effect. In fact, the accumulation of free radicals reduces the tensile strength of the lesions by inhibiting hyaluronic acid, thus preventing tissutal reparative processes. Healing of skin lesions apparently occurs through a first "inflammatory" phase followed by a neo-angiogenesis and granulation tissue formation phase, with wound contraction and subsequent cicatrization and re-epithelization.
It has now been found that chamomile anti-inflammatory and cicatrising properties are enhanced upon combination with other vegetable components, such as milfoil, malva, large-leaved lime flowers and althaea roots. DISCLOSURE OF THE INVENTION
Object of the present invention are pharmaceutical compositions for topical use containing extracts of chamomile heads (Matricaria recutitά), althaea roots (Althaea officinalis L.), malva flowers (Malva sylvestris), large-leaved lime flowers (Tillia Platyphyllos) and milfoil flowers (Achillea millefolium L.), useful for the treatment of skin infiammations and lesions.
Said pharmaceutical compositions are preferably in the form of creams, gels, pastes or ointments, in which the extracts total content ranges from 10 to 40%.
A preferred embodiment of the invention consists in a cream containing 20% extracts in Essex® base cream (hereinafter referred to as BAR 2). The compositions can be prepared from extracts of each vegetable component, or from an extract obtainable from a mixture of all the vegetable components.
Moreover, it is an object of the present invention a process for the preparation of an extract of chamomile heads (Matricaria recutita), althaea roots
(Althaea officinalis L.), malva flowers (Malva sylvestris), large-leaved lime flowers (Tillia Platyphyllos) and milfoil flowers (Achillea millefolium L.) comprising soaking a mixture of the vegetable components, preferably in equal amounts, in an extraction mixture consisting of distilled water and ethyl alcohol. The vegetable components/extraction mixture ratio ranges from 1:8 to 1 : 12 w/v, whereas the distilled water/ethyl alcohol ratio ranges from 10:90 to 50:50 v/v, preferably 30:70 v/v. After soaking for 22 - 26 hours, preferably 24 hours, the liquid phase is recovered by filtration, preferably under vacuum, and evaporated under reduced pressure at a temperature not higher than 35°C. According to a preferred embodiment of the invention, 100 g vegetable components mixture is soaked in a 30/70 v/v distilled water/ethanol mixture, up to 1 litre final volume.
After 24 hours the liquid phase is recovered by filtration under vacuum and evaporated under reduced pressure. The resulting extract is hereinafter referred to as BAR 1. The anti-inflammatory and cicatrising properties of the compositions containing the extracts of the invention were evaluated in rats by means of the following tests:
Carrageenin oedema test (table 1) Dextran oedema test (table 2) - Skin excoriations test (table 3)
Skin ulcers test (table 4) The antiphlogistic effect was evidenced in tests using the extract BAR 1, whereas the cicatrising effect was evidenced in tests using the cream BAR 2, because it adheres better to the treated skin and allows more thorough inspection, due to its more transparent colour than BAR l 's.
Both the extract and the cream showed active, in fact topical application on rat skin reduced in a statistically significant way inflammation and oedema in the carrageenin and dextran oedema tests and enhanced the cicatrising action in the experimental excoriations and ulcers tests.
It is therefore a further object of the present invention the use of the extract obtainable according to the above described process for the preparation of medicaments for the topical use, in particular for the treatment of skin inflammations and/or lesions.
The invention is hereinafter illustrated in more detail by the following examples.
EXAMPLES
Example 1; Preparation of BAR 1 extract BAR 1 extract was prepared soaking for 24 hours a mixture consisting of 100 g of each vegetable component, suitably ground, in distilled water and ethyl alcohol (30:70 v/v), to a final volume of one litre, stored in a tightly sealed dark vessel.
After soaking, the liquid phase was recovered by filtration under vacuum and the intense green liquid was evaporated under reduced pressure at a temperature of 30-35°C, to avoid degradation.
Example 2: Preparation of Cream BAR 2
Cream BAR 2 was prepared incorporating 20 g of BAR 1 extract in
80 g of Essex® base cream. Example 3: Pharmacological tests
Animals
The experiments hereinafter described were carried out on male Sprague-Dawley rats, (about 120-150 g weight) purchased from Harlan Italy (Udine, Italy), housed in single cages, under controlled temperature and humidity (22±1°C, 60% humidity).
Treatments BAR 1 extract or Cream BAR 2 were applied on the area to be treated.
Carrageenin oedema test
A suspension of carrageenin (0.1 ml, 1% in normal saline) was administered to one of the rats hind paws.
The leg volume was evaluated with a pletismometer (Basile, Varese), prior to carrageenin injection (reference value) and after 2, 4, 8, 24 hours. The values reported in the table refer to percentage increases in the paw volume compared with the reference value. BAR 1 extract was applied to the rat paw immediately after carrageenin injection and after each evaluation. Dextran oedema test
A 5% dextran solution (0.1 ml) in saline was administered to one of the rats hind paws.
The leg volume was evaluated with a pletismometer (Basile, Varese), prior to dextran injection (reference value) and after 2, 4, 8, 24 hours. The values reported in the table refer to percentage increases in the leg volume compared with the reference value. BAR 1 extract was applied to the rat paw immediately after carrageenin injection and after each evaluation.
Skin excoriations test
Animals were anaesthetised with Ketavet (Gellini pharmaceutical), then shaved on the back so as to define a 1.5 cm diameter circular area. After that, the skin was scarified with a scalpel, then Essex® base cream was applied to control animals, whereas BAR 2 was applied to the treated ones.
Applications were repeated twice a day for 5 days. The cicatrising activity of BAR 2 was evaluated at 48, 72 and 96 hours from excoriations, using an arbitrary numerical scale (from 0 to 4), according to what described in Tamburini M. et al (Acta Phytoter. 3: 116-121 :2000).
Skin ulcers test Animals were anaesthetised with Ketavet (Gellini pharmaceutical), and shaved on the back, then an incision of 1.5 cm length was performed. Essex® base cream was applied to controls, whereas BAR 2 was applied to treated animals. Applications were repeated twice a day for 5 days. The reparative cicatrising activity of BAR 2 was evaluated at 48, 72 and 96 hours from incision, using an arbitrary numerical scale (from 0 to 4), according to what described in Tamburini M. et al (Acta Phytoter. 3: 116-121 :2000).
Results
Anti-inflammatory activity
Table 1 shows that in a 24 hours evaluation BAR 1 reduces carrageenin-induced oedema in a statistically significant way compared with controls, at any surveying time.
Moreover, BAR 1 significantly reduces (table 2) the percentage of paw volume increase induced by dextran, and is particularly active between 4-6 hours. Table N°l: Effect induced by BAR 1 on carrageenin oedema in rats
Figure imgf000007_0001
Statistical analysis : Student's T Table N° 2: Effect induced by BAR 1 on dextran oedema in rats
Figure imgf000008_0001
Statistical analysis: Student's T Cicatrising activity Table 3 shows that BAR 2 accelerates cutaneous reparative processes subsequent to excoriations. Values observed at 48, 72 and 96 hours from excoriations are in fact much higher in treated animals than in controls. In particular, the effect is statistically significant at 72 and 96 hours.
Moreover, the cream accelerates ulcers cicatrisation (table 4) in a statistically significant way between 72 and 96 hours compared with controls. Table N° 3: Effects of Cream BAR 2 in the skin excoriations test
Figure imgf000008_0002
The reported results refer to average scores obtained using an arbitrary scale (from 0 to 4, wherein 4 means complete cicatrization). Statistical analysis: Student's T Table N° 4: Effects of Cream BAR 2 in the experimental skin ulcers test
Figure imgf000009_0001
The reported results refer to average scores obtained using an arbitrary scale (from 0 to 4, wherein 4 means complete cicatrization). Statistical analysis: T di Student
Conclusions
The results show that BAR 1 extract and the topical pharmaceutical compositions containing it have excellent antiphlogistic and cicatrising activities. Therefore, the pharmaceutical compositions containing the extracts of the invention, in particular BAR 1 extract, can be used in the treatment of skin conditions wherein reduction of inflammation and improvement of tissue repair processes are required, in particular for healing bedsores.

Claims

1. Pharmaceutical compositions for the topical use containing extracts of chamomile heads (Matricaria recutita), althaea roots (Althaea officinalis L.), malva flowers (Malva sylvestris), large-leaved lime flowers (Tillia Platyphyllos) and milfoil flowers (Achillea millefolium L.).
2. Pharmaceutical compositions as claimed in claim 1, in the form of creams.
3. A process for the preparation of an extract of chamomile heads (Matricaria recutita), althaea roots (Althaea officinalis L.), malva flowers
(Malva sylvestris), large-leaved lime flowers (Tillia Platyphyllos) and milfoil flowers (Achillea millefolium L.) comprising the following steps: a. mixing the single vegetable components; b. soaking the vegetable components in a distilled water - ethanol mixture; c. filtering; d. evaporating off the water - ethanol phase.
4. A process as claimed in claim 3, wherein the vegetable components are mixed in equal amounts.
5. A process as claimed in claim 4, wherein the distilled water-ethanol ratio ranges from 10:90 to 50:50 v/v.
6. A process as claimed in claim 4, wherein the distilled water-ethanol ratio is 30:70 v/v.
7. A process as claimed in any one of claims 4 - 6 wherein soaking is carried out for a time ranging from 22 to 26 hours.
8. A process as claimed in any one of claims 4 - 6 wherein soaking is carried out for 24 hours.
9. A process as claimed in any one of claims 4 - 8 wherein evaporation of the water-ethanol phase is carried out at a temperature not higher than 35°C.
10. An extract obtainable with the process of any one of claims 3) - 9).
11. Use of extracts of chamomile heads (Matricaria recutita), althaea roots (Althaea officinalis L.), malva flowers (Malva sylvestris), large-leaved lime flowers (Tillia Platyphyllos) and milfoil flowers (Achillea millefolium L.) for the preparation of medicaments for the treatment of skin inflammations and ulcers.
PCT/EP2002/011357 2001-10-17 2002-10-10 Pharmaceutical compositions for the topical use containing medicinal plants extracts with antiphlogistic and cicatrising activities WO2003033007A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT2001MI002142A ITMI20012142A1 (en) 2001-10-17 2001-10-17 PHARMACEUTICAL COMPOSITIONS FOR TOPICAL USE CONTAINING EXTRACTS OF HERBAL MEDICINES WITH ANTI-LOGISTIC AND CICATRIZING ACTIVITY
ITMI2001A002142 2001-10-17

Publications (1)

Publication Number Publication Date
WO2003033007A1 true WO2003033007A1 (en) 2003-04-24

Family

ID=11448511

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2002/011357 WO2003033007A1 (en) 2001-10-17 2002-10-10 Pharmaceutical compositions for the topical use containing medicinal plants extracts with antiphlogistic and cicatrising activities

Country Status (2)

Country Link
IT (1) ITMI20012142A1 (en)
WO (1) WO2003033007A1 (en)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006047470A3 (en) * 2004-10-26 2006-06-22 Johnson & Johnson Consumer Compositions containing malva sylvestris extract and use thereof on skin or mucosal tissues
WO2007112204A3 (en) * 2006-03-23 2007-11-29 Johnson & Johnson Consumer Ingestible compositions containing extracts
EP1967187A1 (en) 2007-03-06 2008-09-10 Rachid Ennamany Composition based on rutin and L-lysine
JP2008285424A (en) * 2007-05-15 2008-11-27 Maruzen Pharmaceut Co Ltd Profilaggrin production promoter, filaggrin production promoter and cyclooxygenase 2 activity inhibitor
WO2008146009A1 (en) 2007-06-01 2008-12-04 Insignion Holdings Limited Plant extract and its therapeutic use
KR100967018B1 (en) 2003-04-09 2010-06-30 애경산업(주) Skin whitening cosmetics containing plant extracts
US20150265668A1 (en) * 2011-05-16 2015-09-24 Haus Bioceuticals, Inc. Compositions of herbal formulations and uses thereof
EP3150213A1 (en) 2015-10-01 2017-04-05 Braerg - Groupo Brasileiro de Pesquisas Especializadas Ltda A medicinal composition having antibiotic, anti-inflammatory, and wound healing activity
ITUB20160058A1 (en) * 2016-01-19 2017-07-19 Farm S R L C U S Composition of a preparation for the treatment of insect bites with vasoconstrictive, soothing, anti-inflammatory and anti-reddening activity

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4933177A (en) * 1981-02-27 1990-06-12 Societe Anonyme Dite: L'oreal Cosmetic compositions for the treatment of the hair and skin contain in the form of a powder particles resulting from the pulverization of at least one plant substance and a cohesion agent
RU1561262C (en) * 1980-10-13 1994-10-30 Научно-производственное объединение "ВНИИ лекарственых и ароматических растений" Composition showing antiinflammatory activity
WO1998034591A1 (en) * 1997-02-11 1998-08-13 The Procter & Gamble Company Skin lightening compositions
US5876703A (en) * 1994-12-02 1999-03-02 Kao Corporation Flavanonol derivatives and hair-nourishing, hair-growing compositions containing the derivatives

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU1561262C (en) * 1980-10-13 1994-10-30 Научно-производственное объединение "ВНИИ лекарственых и ароматических растений" Composition showing antiinflammatory activity
US4933177A (en) * 1981-02-27 1990-06-12 Societe Anonyme Dite: L'oreal Cosmetic compositions for the treatment of the hair and skin contain in the form of a powder particles resulting from the pulverization of at least one plant substance and a cohesion agent
US5876703A (en) * 1994-12-02 1999-03-02 Kao Corporation Flavanonol derivatives and hair-nourishing, hair-growing compositions containing the derivatives
WO1998034591A1 (en) * 1997-02-11 1998-08-13 The Procter & Gamble Company Skin lightening compositions

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
AERTGEERTS, J.: "Résultats obtenus avec le Kamillosan(R), un extrait standardisée de camomille, en pratique dermatologique", ARS MEDICI, vol. 39, 1984, pages 65 - 68, XP001122220 *
DATABASE WPI Section Ch Week 199523, Derwent World Patents Index; Class B04, AN 1995-176551, XP002228065 *
DELLA LOGGIA R ET AL: "THE ROLE OF FLAVONOIDS IN THE ANTIINFLAMMATORY ACTIVITY OF CHAMOMILLA-RECUTITA", PROGRESS IN CLINICAL AND BIOLOGICAL RESEARCH, 1986, pages 481 - 484, XP001122218, ISSN: 0361-7742 *
TUBARO A ET AL: "EVALUATION OF ANTIINFLAMMATORY ACTIVITY OF A CHAMOMILE CHAMOMILLA-RECUTITA EXTRACT AFTER TOPICAL APPLICATION", PLANTA MEDICA, vol. 51, no. 4, 1984, pages 359, XP009004098, ISSN: 0032-0943 *

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100967018B1 (en) 2003-04-09 2010-06-30 애경산업(주) Skin whitening cosmetics containing plant extracts
WO2006047470A3 (en) * 2004-10-26 2006-06-22 Johnson & Johnson Consumer Compositions containing malva sylvestris extract and use thereof on skin or mucosal tissues
US7754248B2 (en) 2004-10-26 2010-07-13 Johnson & Johnson Consumer Companies, Inc. Ingestible compositions containing extracts
WO2007112204A3 (en) * 2006-03-23 2007-11-29 Johnson & Johnson Consumer Ingestible compositions containing extracts
EP1967187A1 (en) 2007-03-06 2008-09-10 Rachid Ennamany Composition based on rutin and L-lysine
JP2008285424A (en) * 2007-05-15 2008-11-27 Maruzen Pharmaceut Co Ltd Profilaggrin production promoter, filaggrin production promoter and cyclooxygenase 2 activity inhibitor
CN101687001A (en) * 2007-06-01 2010-03-31 因塞尼昂控股有限公司 Plant extract and its therapeutic use
WO2008146009A1 (en) 2007-06-01 2008-12-04 Insignion Holdings Limited Plant extract and its therapeutic use
AU2008256536B2 (en) * 2007-06-01 2011-04-21 Insignion Holdings Limited Plant extract and its therapeutic use
RU2438692C2 (en) * 2007-06-01 2012-01-10 Инсайнион Холдингз Лимитед Vegetable extract and its therapeutic application
US8591966B2 (en) 2007-06-01 2013-11-26 Insignion Holdings Limited Composition containing oils of chamomile flower and black cumin with reduced endotoxins
US20150265668A1 (en) * 2011-05-16 2015-09-24 Haus Bioceuticals, Inc. Compositions of herbal formulations and uses thereof
US9889174B2 (en) * 2011-05-16 2018-02-13 Haus Bioceuticals, Inc. Compositions of herbal formulations and uses thereof
EP3150213A1 (en) 2015-10-01 2017-04-05 Braerg - Groupo Brasileiro de Pesquisas Especializadas Ltda A medicinal composition having antibiotic, anti-inflammatory, and wound healing activity
ITUB20160058A1 (en) * 2016-01-19 2017-07-19 Farm S R L C U S Composition of a preparation for the treatment of insect bites with vasoconstrictive, soothing, anti-inflammatory and anti-reddening activity

Also Published As

Publication number Publication date
ITMI20012142A1 (en) 2003-04-17

Similar Documents

Publication Publication Date Title
Raina et al. Medicinal plants and their role in wound healing
Agyare et al. African medicinal plants with wound healing properties
Abdulla et al. Role of Ficus deltoidea extract in the enhancement of wound healing in experimental rats
Vaisakh et al. The invasive weed with healing properties: A review on Chromolaena odorata
US20190008906A1 (en) Compositions for management of wounds, skin diseases, dehydration, chronic diseases, and respiratory diseases
Nasiry et al. Anti-inflammatory and wound-healing potential of golden chanterelle mushroom, Cantharellus cibarius (Agaricomycetes)
EP2008661A2 (en) Formulation based on marigold aloe and centellae
KR101229992B1 (en) Herbal formulation for wound healing
CN105232411A (en) A kind of natural plant preservative composition and its application in cosmetics
Mathew et al. Evaluation of anti-inflammatory and wound healing activity of Gentiana lutea rhizome extracts in animals
Mishra et al. Efficacy of hydrogel containing rutin in wound healing
WO2003033007A1 (en) Pharmaceutical compositions for the topical use containing medicinal plants extracts with antiphlogistic and cicatrising activities
EP3247211A1 (en) Microbicidal oil-in-water dispersion
Adiele et al. Wound healing effect of methanolic leaf extract of Napoleona vogelii (Family: Lecythidaceae) in rats
DE102021200975B4 (en) Biologically-based wound closure preparation
Herman et al. Herbal Products in Postsurgical Wound Healing–Incision, Excision and Dead Space Wound Models
US6699512B2 (en) Hypericum perforatum l. oleoresin, procedure for obtaining it and uses of it
Bist et al. Embelia ribes: A valuable medicinal plant
Gastaldi et al. Solidago chilensis Meyen (Asteraceae), a medicinal plant from South America. A comprehensive review: ethnomedicinal uses, phytochemistry and bioactivity
Chowdhary et al. Wound healing activity of aqueous extracts of Ficus religiosa and Ficus benghalensis leaves in rats
US7344737B2 (en) Herbal composition for cuts, burns and wounds
Ullah et al. Medicinal benefits of lemon balm (Melissa officinalis) for human health
Bairy Wound healing potentials of plant products
KR20210077365A (en) Cosmetic composition comprising colocasia esculenta biorenovate extract and method of preparing the same
CN115844777A (en) Itching-relieving, antibacterial and anti-inflammatory composition containing plant extract and application thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VC VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载